Trends of Rifampicin Resistance in Patients with Pulmonary Tuberculosis: A Longitudinal Analysis Based on Drug Resistance Screening in Eastern China Between 2015 and 2019

• DOI: 10.2147/idr.s394089
• Publication Date: 2022-12-28T02:05:10Z
• Authors: Yanli Ren; Bin Chen; Jiaying Zhao; Xiaohua Tan; Xinyi Chen; Lin Zhou; Fei Wang; Ying Peng; Jianmin Jiang
• Keywords: 0303 health sciences; 03 medical and health sciences; Infection and Drug Resistance; drug-resistant tuberculosis; ofloxacin; Infectious and parasitic diseases; RC109-216; trend analysis; rifampicin; Original Research; 3. Good health

To understand the trend of overall rifampicin resistance rates for tuberculosis in Zhejiang Province between 2015 and 2019.The basic demographic information patients with who were screened drug January 1, December 31, 2019 was collected through national Tuberculosis Information Management System. The data processed analyzed using IBM SPSS 26.0 GeoDa 1.14 software.The total rate 5.9% 53,893 validated cases screening conducted pulmonary during study period. There a decreasing both initial re-treated (P<0.001), but higher TB than receiving their treatment (11.4% vs 4.2%). steadily decreased all prefectures, there significant upward use Xpert MTB/RIF rapid assay. An increasing also identified ofloxacin co-resistance (P<0.001).The rifampin past five years has shown trend, to high. Resistance testing fluoroquinolones should be carried out as early possible whose diagnosis results indicate resistance, more effective second-line plans developed based on this testing.